M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
Daniele Santini,Francesco Graziano,Vincenzo Catalano,M. Di Seri,E. Testa,Anna Maria Baldelli,Paolo Giordani,A. La Cesa,Bruno Spalletta,Bruno Vincenzi,Antonio Russo,Michele Caraglia,Vladimir Virzì,Stefano Cascinu,Giuseppe Tonini +14 more
TL;DR: OXALF represents an active and well-tolerated treatment modality for elderly patients with locally advanced and metastatic gastric cancer and the time to disease progression and the survival time.
Book ChapterDOI
Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy
TL;DR: The data strongly suggest that the post-translational modifications of eIF-5A could be a suitable target for the potentiation of the activity of anti-cancer agents.
Journal ArticleDOI
Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies
Giovanni D'Arena,Candida Vitale,Marta Coscia,Agostino Festa,Nicola Matteo Dario Di Minno,Vincenzo De Feo,Michele Caraglia,Gioacchino Calapai,Luca Laurenti,Pellegrino Musto,Giovanni Di Minno,Daniela Fenoglio +11 more
TL;DR: The heterogeneity of the experimental approaches that were used explains—at least in part—the discordant results reported by different groups that have investigated the role of Tregs in hematological malignancies and in cancer in general.
Journal ArticleDOI
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Pierpaolo Correale,Cinzia Remondo,Salvatore Francesco Carbone,Veronica Ricci,Cristina Migali,Ignazio Martellucci,Antonella Licchetta,Raffaele Addeo,Luca Volterrani,Giuseppe Gotti,Maria Saveria Rotundo,Pierfrancesco Tassone,Pasquale Sperlongano,Alberto Abbruzzese,Michele Caraglia,Pierosandro Tagliaferri,Guido Francini +16 more
TL;DR: The combination of bevacizumab with a dose/dense chemotherapy regimen resulted moderately safe but showed significant anti-angiogenic, and anti-tumor activity.
Journal ArticleDOI
S-Adenosylmethionine-mediated apoptosis is potentiated by autophagy inhibition induced by chloroquine in human breast cancer cells.
Donatella Delle Cave,Vincenzo Desiderio,Laura Mosca,Concetta Paola Ilisso,Luigi Mele,Michele Caraglia,Giovanna Cacciapuoti,Marina Porcelli +7 more
TL;DR: Autophagy can act as an escape mechanism from the apoptotic activity of Ado met, and that AdoMet could be used in combination with CLC or its analogs in the treatment of breast cancer.